Treace Medical Concepts (TMCI) Earnings Analysis
Treace Medical Concepts (TMCI) next reports earnings on 2026-08-06, consensus EPS -0.3 USD. Last quarter (2026-05-08) it beat with EPS -0.28 USD vs -0.31 USD est (+9.7%). It has beaten estimates in 5/5 recent quarters (100%). Trailing P/E -4.09.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does TMCI next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | -0.3 USD |
| Revenue estimate | 0.04B |
TMCI earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-08 | -0.28 USD | -0.31 USD | +9.7% | Beat |
| 2026-02-27 | -0.12 USD | -0.1519 USD | +21% | Beat |
| 2025-11-06 | -0.26 USD | -0.28 USD | +7.1% | Beat |
| 2025-05-08 | -0.25 USD | -0.31 USD | +19.4% | Beat |
| 2025-02-27 | -0.01 USD | -0.04 USD | +75% | Beat |
Beat rate: 5/5 (100%) over reported quarters with consensus data.
TMCI valuation and analyst view
| Trailing P/E | -4.09 |
|---|---|
| Trailing EPS | -0.94501 USD |
| Price / book | 3.32 |
| Dividend yield | 0.00% |
| Market cap | 0.26B |
| Analyst consensus | Hold (2 buy / 6 hold / 1 sell) |
| Avg price target | 5 USD |
Related research pages
Frequently asked questions
When is Treace Medical Concepts (TMCI)'s next earnings date?
Treace Medical Concepts is next scheduled to report on 2026-08-06, with a consensus EPS estimate of -0.3 USD and revenue estimate of 0.04B.
Did TMCI beat earnings last quarter?
In its 2026-05-08 report, TMCI posted EPS of -0.28 USD versus a -0.31 USD estimate — a beat of 9.7%.
What is TMCI's earnings track record?
Over the last 5 reported quarters with consensus data, TMCI beat estimates 5 times (100%).
What is TMCI's current P/E ratio and EPS?
TMCI trades at a trailing P/E of -4.09 on trailing EPS of -0.9450141882173926 USD.
What do analysts rate TMCI?
Analyst consensus is "Hold" across 9 ratings (0 strong buy, 2 buy, 6 hold, 1 sell, 0 strong sell). Average 12-month price target: 5 USD.